5 Key Takeaways

• 1

  Migaldendranib is a subcutaneous therapy for wet AMD and DME, reducing injection burden while preserving vision.

• 2

  The phase 2 study showed that migaldendranib is safe, with no liver or kidney toxicity and minimal side effects.

• 3

  CST decreased significantly in both wet AMD and DME patients, with BCVA improvements noted after treatment.

• 4

  The treatment allows for a single injection to address both eyes, potentially reducing the need for supplemental injections.

• 5

  Migaldendranib represents a novel, first-in-class option for at-home treatment of AMD and DME.